The Leukemia & Lymphoma Society (LLS) has invested over $1.5 billion in blood cancer research since its founding, making it the largest nonprofit funder of blood cancer science in the world. If you’re searching for advances and insights from the Lymphoma and Leukemia Society, here’s the bottom line: this organization has directly contributed to 27 of the 75+ FDA-approved blood cancer therapies available today — including landmark treatments like CAR-T cell therapy and targeted small-molecule inhibitors that have fundamentally changed survival rates.
Whether you’re a patient newly diagnosed with lymphoma or leukemia, a caregiver trying to navigate treatment options, or a medical student looking for a research overview, this article breaks down what LLS has accomplished, what’s in the pipeline, and how these advances translate into real clinical outcomes.
Lymphoma vs. Leukemia: A Quick Refresher
Before diving into the breakthroughs, let’s clarify what we’re dealing with. Leukemia starts in the bone marrow and floods the bloodstream with abnormal white blood cells. Lymphoma arises in the lymphatic system — specifically from lymphocytes — and typically presents as enlarged lymph nodes.
Both are blood cancers, but they behave differently, require different staging systems, and respond to different treatments. Here’s a side-by-side comparison:
| Feature | Leukemia | Lymphoma |
|---|---|---|
| Origin | Bone marrow | Lymph nodes / lymphatic tissue |
| Major subtypes | ALL, AML, CLL, CML | Hodgkin (HL), Non-Hodgkin (NHL) |
| Common presentation | Fatigue, infections, bruising, anemia | Painless swollen lymph nodes, night sweats, weight loss |
| Typical age at diagnosis | ALL: children; AML/CLL/CML: adults 60+ | HL: 20–30s; NHL: 60+ |
| 5-year survival (overall) | ~66% | HL: ~89%; NHL: ~74% |
| Key diagnostic test | Bone marrow biopsy + flow cytometry | Lymph node biopsy + imaging (PET/CT) |
7 Major Advances Driven by the Leukemia & Lymphoma Society
1. CAR-T Cell Therapy
LLS was an early funder of chimeric antigen receptor T-cell (CAR-T) therapy, which re-engineers a patient’s own immune cells to attack cancer. FDA-approved CAR-T products like tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) have produced complete remission rates of 40–54% in patients with relapsed or refractory large B-cell lymphoma — patients who previously had almost no options.
2. Targeted Therapies for CLL
The approval of ibrutinib (a BTK inhibitor) in 2013 transformed chronic lymphocytic leukemia treatment. LLS-funded research contributed to the development of this class of drugs, which now includes zanubrutinib and acalabrutinib. These oral medications have largely replaced chemoimmunotherapy as first-line treatment for many CLL patients, with progression-free survival exceeding 5 years in clinical trials.
3. Genomic Profiling and Precision Medicine
LLS’s Pediatric Acute Leukemia (PedAL) initiative and the Beat AML Master Trial use comprehensive genomic profiling to match patients with targeted therapies based on their specific mutations. The Beat AML trial enrolled over 1,000 patients and demonstrated that genetically guided treatment selection improved 30-day mortality compared to standard approaches.
4. Bispecific Antibodies
A new wave of bispecific antibodies — drugs that simultaneously bind cancer cells and T-cells — emerged partly from LLS-supported science. Agents like mosunetuzumab and glofitamab have shown complete response rates of 18–39% in relapsed/refractory follicular lymphoma, offering an “off-the-shelf” alternative to CAR-T therapy.
5. MRD-Guided Treatment
Measurable residual disease (MRD) testing can detect as few as 1 cancer cell among 1 million normal cells. LLS has championed MRD as an endpoint in clinical trials, and it’s increasingly used to determine whether patients can safely stop treatment early or need intensification. In CLL, achieving MRD-undetectable status correlates with significantly longer progression-free survival.
6. Health Equity and Access Initiatives
LLS’s Myeloma Link and outreach programs target disparities in blood cancer outcomes. Black patients with multiple myeloma, for example, are diagnosed at twice the rate of white patients but historically have had lower access to stem cell transplantation. LLS-funded programs aim to close these gaps through clinical trial diversity, patient navigation services, and copay assistance — distributing over $100 million annually in financial support.
7. Children’s Initiative and Next-Generation Pediatric Trials
While pediatric ALL cure rates now exceed 90%, certain subtypes remain deadly. LLS’s Children’s Initiative has invested over $200 million specifically in pediatric research, funding trials of novel agents for high-risk subtypes like infant ALL with KMT2A rearrangements, where survival is still below 50%.
What Causes Lymphoma and Leukemia?
The honest answer: we don’t fully know. Most cases arise from acquired somatic mutations — genetic changes that accumulate over a lifetime rather than being inherited. Known risk factors include:
- Radiation exposure — atomic bomb survivors had markedly increased leukemia rates within 5–10 years
- Chemical exposure — benzene is a well-established cause of AML
- Viral infections — Epstein-Barr virus (linked to Hodgkin and Burkitt lymphoma), HTLV-1 (adult T-cell leukemia)
- Prior chemotherapy — alkylating agents and topoisomerase II inhibitors can cause therapy-related myeloid neoplasms
- Genetic predisposition — Down syndrome carries a 10- to 20-fold increased risk of leukemia; Li-Fraumeni syndrome increases lymphoma risk
- Immunosuppression — organ transplant recipients have a 3- to 5-fold higher risk of NHL
Most patients diagnosed with lymphoma or leukemia have no identifiable cause. That can be frustrating to hear, but it also means there’s usually nothing you did — or didn’t do — to cause this.
How These Cancers Are Diagnosed Today
Diagnosis has moved well beyond simple blood counts. A modern workup typically includes:
- Complete blood count (CBC) with differential — the starting point; may reveal abnormal white cell counts, anemia, or thrombocytopenia
- Peripheral blood smear — a pathologist reviews cell morphology under the microscope
- Flow cytometry / immunophenotyping — identifies surface markers on abnormal cells to classify the exact subtype
- Bone marrow biopsy — essential for leukemia staging and increasingly used for lymphoma
- Cytogenetics and FISH — detects chromosomal abnormalities like the Philadelphia chromosome (BCR-ABL1) in CML
- Next-generation sequencing (NGS) — identifies targetable mutations (e.g., FLT3, IDH1/2 in AML; TP53 in CLL)
- PET/CT imaging — standard for lymphoma staging using the Lugano classification
Getting the subtype right matters enormously. Treatment for Hodgkin lymphoma looks completely different from treatment for mantle cell lymphoma, even though both are “lymphoma.”
When to See a Doctor
Don’t wait on symptoms that could signal a blood cancer. See your doctor promptly if you experience:
- Persistent, painless swelling of lymph nodes lasting more than 2–3 weeks
- Unexplained fevers, drenching night sweats, or weight loss exceeding 10% of body weight over 6 months (these are called “B symptoms”)
- Unusual fatigue that doesn’t improve with rest
- Frequent or severe infections
- Easy bruising, petechiae (tiny red spots under the skin), or prolonged bleeding
- Bone pain, especially in the sternum or long bones
A simple CBC can often provide the first clue. If abnormalities are found, ask for a referral to a hematologist-oncologist — not just a general oncologist. Blood cancers are complex, and subspecialty expertise makes a measurable difference in outcomes.
How LLS Can Help You Right Now
Beyond research, LLS offers direct patient services that are genuinely useful:
- Information Specialists — oncology nurses and social workers available at 1-800-955-4572
- Financial assistance — copay programs, travel assistance, and urgent need grants
- Clinical trial navigation — help finding and enrolling in appropriate trials through their Clinical Trial Support Center
- Peer-to-peer support — matching patients with trained volunteers who’ve been through similar diagnoses
- Free educational materials — disease-specific booklets reviewed by medical experts
Frequently Asked Questions
Does the Leukemia & Lymphoma Society help with costs?
Yes. LLS provides direct financial assistance including copay support, travel grants for treatment, and urgent-need funding. In 2023, the organization distributed over $100 million in patient financial aid. You can apply through their website or by calling their Information Resource Center.
What research is LLS funding right now?
Current priorities include next-generation CAR-T therapies, bispecific antibodies, MRD-driven treatment strategies, health equity initiatives, and the Beat AML and PedAL precision medicine trials. LLS also funds early-career researchers through its Scholar and Fellow grants — an investment that has launched the careers of multiple Nobel Prize winners in medicine.
Is lymphoma or leukemia more curable?
It depends entirely on the subtype. Hodgkin lymphoma has a cure rate exceeding 85%. Childhood ALL is cured in over 90% of cases. On the other hand, AML in older adults and certain aggressive NHL subtypes still carry 5-year survival rates below 30%. The word “curable” is far more meaningful when you specify the exact diagnosis.
Can LLS help me find a clinical trial?
Absolutely. LLS operates a Clinical Trial Support Center staffed by nurse navigators who conduct personalized searches based on your diagnosis, treatment history, and location. This is a free service and one of the most underutilized resources they offer.
How is LLS different from other cancer charities?
LLS focuses exclusively on blood cancers — leukemia, lymphoma, myeloma, and myelodysplastic syndromes. This specialization means their research funding, patient education, and advocacy efforts are concentrated rather than spread across dozens of cancer types. They also have a strong track record: therapies first developed for blood cancers through LLS-funded research (like immunotherapy and targeted therapy) have since been adapted for solid tumors.
